Acetaminophen Chlorpheniramine Maleate Phenylephri

證據等級: L5

預測適應症: 0 個

ACETAMINOPHEN + CHLORPHENIRAMINE MALEATE + PHENYLEPHRINE: Combination Cold Remedy — Insufficient Data for Repurposing Evaluation

One-Sentence Summary

ACETAMINOPHEN + CHLORPHENIRAMINE MALEATE + PHENYLEPHRINE is a classic three-component OTC cold and flu combination, pairing an analgesic/antipyretic, an antihistamine, and a nasal decongestant. The TxGNN pipeline returned no predicted new indications for this combination, and the drug is not registered in the queried regulatory database. Due to the absence of predicted indications, clinical trial evidence, and regulatory records, no repurposing evaluation can be completed at this stage.

Quick Overview

Item	Content
Original Indication	Not available (no regulatory records found)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — but even this is absent)
US Market Status	Not marketed (0 licenses found)
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

This combination presents two likely reasons why TxGNN produced no output:

1. Multi-ingredient query limitation. The query was submitted as a combined string (ACETAMINOPHEN; CHLORPHENIRAMINE MALEATE; PHENYLEPHRINE). TxGNN operates on single drug nodes mapped to DrugBank IDs. A multi-ingredient string typically fails to resolve to any node in the knowledge graph, resulting in zero predictions. Each component would need to be queried individually.

2. No DrugBank ID resolved. The Evidence Pack confirms drugbank_id: null. Without a DrugBank node anchor, the knowledge graph traversal cannot begin — there is no starting point from which to score disease associations.

As a result, this report cannot proceed with a standard repurposing evaluation. The sections below document the data gaps and the remediation steps required.

US Market Information

No regulatory records were found in the queried database for this combination. This does not necessarily mean the components are unapproved — acetaminophen, chlorpheniramine, and phenylephrine are each individually well-established OTC ingredients with long regulatory histories in multiple jurisdictions — but this exact combination product returned zero results.

Authorization Number	Product Name	Dosage Form	Approved Indication
—	No records found	—	—

Safety Considerations

Please refer to the package insert for safety information. No safety data, key warnings, contraindications, or drug interaction records were returned for this query. Individual component package inserts should be consulted directly.

Conclusion and Next Steps

Decision: Hold

Rationale: The pipeline could not resolve this multi-ingredient string to a DrugBank node, so TxGNN generated no predictions and no repurposing evaluation is possible. This is a data pipeline issue, not a negative signal about the drug’s repurposing potential.

To proceed, the following is needed:

Decompose the query: Re-run TxGNN separately for each component — ACETAMINOPHEN (DrugBank: DB00316), CHLORPHENIRAMINE MALEATE (DrugBank: DB01114), and PHENYLEPHRINE (DrugBank: DB00388) — and aggregate results
Resolve DrugBank IDs: Confirm correct DrugBank IDs for all three components to enable knowledge graph traversal
Re-query regulatory database: Search each INN individually; individual component registrations are likely present
Clarify evaluation scope: Determine whether the repurposing target is the combination product or one of its individual components; the combination’s pharmacological profile is dominated by its separate mechanisms and synergies rather than a unified MOA
Obtain MOA data: Pull DrugBank mechanism entries for each component to support a downstream mechanistic rationale once predictions are available
Safety data retrieval: Download package insert PDFs from the regulatory authority to populate warnings and contraindication fields
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.